Illumina Launches the Human CNV370-Duo DNA Analysis BeadChip for Copy Number Variation Research.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Illumina, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ILMN) today announced the launch of a new DNA Analysis DNA analysis Any technique used to analyze genes and DNA. See Chromosome walking, DNA fingerprinting, Footprinting, In situ hybridization, Jeffries' probe, Jumping libraries, PCR, RFLP analysis, Southern blot hybridization. BeadChip developed in collaboration with deCODE genetics deCODE genetics, Inc. (Íslensk erfðagreining in Icelandic) NASDAQ: DCGN is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 to identify human genes associated with common diseases using population studies, and apply the . The new product, called the HumanCNV370-Duo, is the world's first microarray designed to specifically target novel regions of the genome that show copy number variation (CNV CNV Choroidal Neovascularization (eye disorder) CNV Christelijk Nationaal Vakverbond CNV Copy Number Variation CNV Conveyor CNV Chief of Navy CNV Continuous Normal Voltage CNV Crypto Net Variable CNV Could Not Verify ). Copy number variations can occur when a region within a chromosome or an entire chromosome is randomly amplified or deleted. DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. copy number of certain genomic regions can vary widely from person to person and has already been linked to cancers, congenital disorders List of congenital disorders Numerical
Powered by Illumina's Infinium([R]) Assay, the HumanCNV370-Duo enables researchers to analyze two samples simultaneously and access novel content for detecting disease-relevant CNV regions. Content found on this BeadChip will also be available on Illumina's Human 1M, a single-chip solution that will profile over one million diverse genetic variants. "Before the HumanCNV370-Duo was developed, we did not have a tool that could target select regions of the genome that we believe contain the majority of undiscovered CNVs. Preliminary data from this array demonstrate that we can identify numerous novel CNV regions that were notoriously difficult to define using previous technologies and can look for new disease-associated genes and markers," said Jeffrey Gulcher, M.D., Ph.D., Chief Scientific Officer of deCODE genetics. "Illumina's HumanCNV370-Duo will offer researchers superior quality and content as compared to any other CNV products currently available. We look forward to providing our contract genotyping customers the full benefit of this new and exciting product." The HumanCNV370-Duo combines the content found on the HumanHap300-Duo with an additional 55,000 markers specifically designed to target approximately 11,000 novel copy number variant regions. In addition to providing broad coverage of SNPs from the International HapMap Project The International HapMap Project is an organization whose goal is to develop a haplotype map of the human genome (the HapMap), which will describe the common patterns of human genetic variation. , the HumanCNV370-Duo also provides coverage for regions of the human genome believed to contain the majority of undiscovered CNVs. "Studying copy number variation adds a new level of information to DNA Analysis, and integrating this information into genotyping studies is essential. Researchers are now looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. a tool that can help them identify CNVs found in unstable genomic regions that are difficult to define by current technologies," said Daniel Peiffer, Ph.D., Associate Product Manager for DNA Products at Illumina. "By working closely with deCODE and accessing their large set of validated CNV regions not currently available in any public repository, we have been able to specifically select a set of regions that are highly likely to represent functional variants for common and rare diseases." "We have had a long-standing relationship with deCODE and worked very closely with them to develop novel content for the HumanCNV370-Duo," said Jay Flatley, President and Chief Executive Officer of Illumina. "By adding this BeadChip to our growing product portfolio, we have quickly evolved our technologies to meet the needs of the life sciences community through a successful collaboration with a global leader in gene discovery." About Copy Number Variation Research from the past several years show that human copy number variation contributes to a high level of genetic variation. In addition to the information gained from SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily genotyping studies, CNVs will provide additional insights into how large-scale genetic diversity impacts biological function and contributes to both complex and common human diseases. About Infinium Genotyping and CNV Analysis Infinium Genotyping utilizes a novel assay together with Illumina's BeadArray(TM) technology to deliver industry-leading performance, genome-wide access and scalable solutions for SNP genotyping and the analysis of CNV. The revolutionary Infinium Assays and corresponding BeadChips allow large-scale interrogation interrogation In criminal law, process of formally and systematically questioning a suspect in order to elicit incriminating responses. The process is largely outside the governance of law, though in the U.S. of variation in the human genome, accelerating the ability of researchers to cost-effectively unlock the genetic basis of disease. For more information on Infinium technology and products, visit www.illumina.com/infinium. About Illumina Illumina (www.illumina.com) is developing next-generation tools for the large-scale analysis of genetic variation and function. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. with Affymetrix, our ability to effectively integrate our recent acquisition of Solexa, Inc., Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, Illumina's ability to manufacture robust Sentrix(R) arrays and Oligator(R) oligonucleotides, Illumina's ability to scale and integrate CyVera technology, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion